In summary, TyG and Prdx1 were identified as important predictors of NAFLD remission, which could be used as an early non-invasive marker or as adjuncts to liver biopsy to confirm NAFLD remission. Here, PRDX1 is linked to metabolic dysfunction-associated steatotic liver disease.